Patients with suspected PH should undergo two 6MWTs to improve the accuracy of exercise capacity measurements.
The 6-minute walk test had prognostic value with respect to mortality in a population of patients with pulmonary arterial hypertension.
Individuals treated with riociguat for pulmonary hypertension may have a greater risk for gastrointestinal disorders compared with tadalafil and sildenafil.
Brain natriuretic peptide levels may accurately predict 5-year survival rates in patients with pulmonary arterial hypertension.
Although the Wells and revised Geneva scores are used in the general population to predict pulmonary embolism, researchers found they were not reliable in pregnant and postpartum women.
Pulmonary hemodynamic changes in chronic thromboembolic pulmonary hypertension may be monitored via the 6-minute walk test.
Bosentan may benefit a subset of patients with idiopathic pulmonary fibrosis-associated pulmonary hypertension.
A clinical trial is underway to assess the safety and efficacy of dabigatran in intermediate-risk pulmonary embolism after completing 72 hours of heparin therapy.
The REVEAL risk score gives significant predictive value for long-term survival and changes in mortality risk in patients with PAH.
A fully implantable programmable intravascular delivery system using treprostinil was found to be highly stable in patients with PAH.
Pulmonary hypertension may be more important than age in predicting heart transplant outcomes.
A study evaluated whether changes in estimated glomerular filtration rate were predictive of mortality in patients with pulmonary arterial hypertension.
Prospective validation research is needed before these clinical predictors of pediatric PE can become guidelines.
A systematic review evaluated whether catheter-directed thrombolysis improved outcomes in patients with intermediate-risk pulmonary emboli.
The use of veno-arterial extracorporeal membrane oxygenation as bridge therapy for massive pulmonary embolism may allow clinicians to better triage patients to appropriate destination therapy.
Individuals who are HIV-positive may be at a higher risk for increased pulmonary pressure and mortality.
A study evaluated the quality of targeted anticoagulation in patients with PAH, and examined outcomes associated with poor time spent within targeted anticoagulation range.
Lung transplantation may be an option in patients with severe pulmonary arterial hypertension who do not respond well to medical therapy.
Select pediatric patients with pulmonary arterial hypertension may benefit from treatment with riociguat.
A 40-year-old woman presents with worsening shortness of breath after being treated with long-acting nifedipine for 2 years.